NHO Revive opens Nebraska’s only site in Johnson & Johnson prostate cancer trial

NHO Revive in Lincoln is now Nebraska’s only site for a Johnson & Johnson Phase 3 study testing pasritamig, an immune therapy for metastatic prostate cancer. The trial could expand access to a new treatment approach for patients whose disease has progressed after standard therapies.

Why it matters: - NHO Revive is giving Nebraska patients access to a late-stage prostate cancer trial that is not available anywhere else in the state. - The study tests a different treatment approach for men whose cancer has continued to progress after standard hormone-based care. - The trial could help define whether pasritamig improves outcomes when added to docetaxel.

What happened: - NHO Revive became Nebraska’s only site for Johnson & Johnson’s Phase 3 KLK2-PASenger trial. - The study is evaluating pasritamig, an investigational immune therapy for prostate cancer. - The site is based in Lincoln. - Dr. Kailash Mosalpura, medical oncologist at Nebraska Hematology-Oncology, said the trial lets the team bring innovative options directly to patients in Lincoln and help advance cancer care for the community.

The details: - Pasritamig is designed to harness T-cells to target cancer cells that express human kallikrein 2, or KLK2. - KLK2 is found on prostate cancer cells. - The treatment approach differs from traditional chemotherapy and hormone-based therapies. - The KLK2-PASenger trial is randomized and open-label. - The study compares pasritamig plus docetaxel with docetaxel alone. - The primary endpoint is time without disease progression on imaging scans. - The study also measures overall survival, quality of life and other response outcomes. - Eligible participants must have histologically confirmed metastatic prostate adenocarcinoma. - Eligible patients must have disease that progressed despite androgen deprivation therapy and at least one prior novel hormonal therapy. - Participants must be 18 or older. - Participants must have an ECOG performance status of 0 or 1.

Between the lines: - Johnson & Johnson is testing pasritamig in a setting where existing treatments have already failed, which suggests the company is targeting a harder-to-treat patient group. - Opening a single Nebraska site can broaden access for patients who might otherwise need to travel out of state for a Phase 3 trial. - The focus on survival, imaging progression and quality of life signals that the study is trying to show both clinical benefit and patient impact.

What's next: - Eligible patients can seek enrollment through NHO Revive. - The trial will continue to evaluate whether the combination of pasritamig and docetaxel outperforms docetaxel alone. - NHO Revive directed readers to more information.